HC Wainwright Has Pessimistic Outlook of ACAD Q2 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Analysts at HC Wainwright cut their Q2 2025 earnings per share estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Thursday, May 8th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will post earnings per share of $0.11 for the quarter, down from their prior estimate of $0.16. HC Wainwright currently has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q3 2025 earnings at $0.17 EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at $0.61 EPS, FY2026 earnings at $1.86 EPS and FY2029 earnings at $2.33 EPS.

A number of other equities research analysts have also recently commented on the company. Morgan Stanley restated an “equal weight” rating and set a $20.00 target price on shares of ACADIA Pharmaceuticals in a research report on Friday, March 7th. Needham & Company LLC restated a “buy” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Tuesday, April 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price target for the company. Finally, UBS Group decreased their price objective on shares of ACADIA Pharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a report on Monday, April 28th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $24.70.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ ACAD opened at $17.44 on Friday. ACADIA Pharmaceuticals has a 1 year low of $13.40 and a 1 year high of $20.68. The company’s fifty day moving average price is $15.83 and its 200 day moving average price is $16.96. The company has a market capitalization of $2.92 billion, a PE ratio of 22.36 and a beta of 0.47.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01. The company had revenue of $244.32 million during the quarter, compared to the consensus estimate of $239.32 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. ACADIA Pharmaceuticals’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 earnings per share.

Institutional Trading of ACADIA Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Exchange Traded Concepts LLC purchased a new stake in ACADIA Pharmaceuticals in the first quarter valued at $29,000. Picton Mahoney Asset Management acquired a new stake in shares of ACADIA Pharmaceuticals during the first quarter valued at about $32,000. Virtus Fund Advisers LLC acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter worth approximately $39,000. Federated Hermes Inc. increased its holdings in ACADIA Pharmaceuticals by 231.5% in the 1st quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,618 shares during the last quarter. Finally, R Squared Ltd acquired a new position in ACADIA Pharmaceuticals during the fourth quarter worth $47,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the sale, the director now directly owns 17,595 shares in the company, valued at $320,756.85. This represents a 21.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Mark C. Schneyer sold 3,171 shares of the business’s stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total value of $54,065.55. Following the transaction, the executive vice president now directly owns 56,889 shares in the company, valued at $969,957.45. This trade represents a 5.28 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,994 shares of company stock worth $313,131. Insiders own 26.50% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.